Study identifier:D0810C00024
ClinicalTrials.gov identifier:NCT00777582
EudraCT identifier:2008-003697-18
CTIS identifier:N/A
A Phase I, Randomised, 2 Period Cross Over Study to Determine the Comparative Bioavailability of Two Different Oral Formulations of AZD2281 in Cancer Patients with Advanced Solid Tumours
Solid Tumors
Phase 1
No
AZD2281
All
197
Interventional
18 Years - 130 Years
Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Dec 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Treatment A 300mg bid (twice daily) tablet dose | Drug: AZD2281 Oral single dose formulation Other Name: Olaparib |
Experimental: Treatment B 400 mg twice daily (bid) capsule dose | Drug: AZD2281 Oral single dose formulation Other Name: Olaparib |
Experimental: Treatment C 400mg bid (twice daily) tablet dose | Drug: AZD2281 Oral single dose formulation Other Name: Olaparib |